- Report
- December 2023
- 200 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1202EUR$1,250USD£1,031GBP
- Clinical Trials
- April 2024
- 65 Pages
Global
From €1442EUR$1,500USD£1,237GBP
- Report
- April 2024
- 98 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1202EUR$1,250USD£1,031GBP
- Report
- January 2022
- 60 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- January 2022
- 112 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- January 2022
- 60 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Drug Pipelines
- August 2020
- 90 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- September 2021
- 256 Pages
Global
From €5931EUR$6,168USD£5,088GBP
The Nasal Polyps Drug market is a subset of the larger Respiratory Drugs market. Nasal Polyps Drugs are used to treat nasal polyps, which are non-cancerous growths in the nasal passages. These drugs are typically administered as a nasal spray or injection, and can reduce the size of the polyps and improve breathing. Commonly used drugs include corticosteroids, antifungal medications, and antibiotics. Nasal Polyps Drugs can also be used to prevent the recurrence of polyps.
The Nasal Polyps Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi, Pfizer, and Novartis. Other companies in the market include AstraZeneca, Boehringer Ingelheim, and Sun Pharmaceuticals. Show Less Read more
